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 Introduction 
 In 1861, Prosper Ménière was the first to ascribe a cer-
tain combination of tinnitus, one-sided hearing loss and 
an extreme feeling of vertigo not to the brain but to the 
inner ear [Ménière, 1861a, b]. Not much later, this triad 
of symptoms was being referred to as ‘maladie de Mé-
nière’, Ménière’s disease [Thorp and James, 2005].
 The most common approach in Europe for the treat-
ment of Ménière’s disease is the continuous oral applica-
tion of betahistine dihydrochloride. Betahistine has been 
used in the treatment of Ménière’s disease for decades; 
hence clinical trials and meta-analyses of its efficacy are 
numerous. It is commonly accepted that repetitive daily 
doses of betahistine are capable of reducing the number 
and gravity of attacks during the course of the disease 
[Claes and Van de Heyning, 1997, 2000; James and Bur-
ton, 2001; James and Thorp, 2005]. 
 However, to this day it is not clear how betahistine acts 
in Ménière’s disease. It has been proposed that betahis-
tine, through its histamine-like properties, might increase 
vascular permeability and thus decrease the endolym-
phatic hydrops that is the cause of Ménière’s disease [Ber-
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 Abstract 
 Objective: Betahistine is a histamine-like drug that is consid-
ered beneficial in Ménière’s disease by increasing cochlear 
blood flow. Acting as an agonist at the histamine H 1 -receptor 
and as an inverse agonist at the H 3 -receptor, these receptors 
as well as the adrenergic α 2 -receptor were investigated for 
betahistine effects on cochlear blood flow.  Materials and 
Methods: A total of 54 Dunkin-Hartley guinea pigs were ran-
domly assigned to one of nine groups treated with a selec-
tion of H 1 -, H 3 - or α 2 -selective agonists and antagonists to-
gether with betahistine. Cochlear blood flow and mean arte-
rial pressure were recorded for 3 min before and 15 min after 
infusion.  Results: Blockage of the H 3 - or α 2 -receptors caused 
a suppression of betahistine-mediated typical changes in co-
chlear blood flow or blood pressure. Activation of H 3 -recep-
tors caused a drop in cochlear blood flow and blood pres-
sure. H 1 -receptors showed no involvement in betahistine-
mediated changes of cochlear blood flow.  Conclusion: 
Betahistine most likely affects cochlear blood flow through 
histaminergic H 3 -heteroreceptors.  © 2015 S. Karger AG, Basel 
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lin et al., 2011]. Moreover, betahistine could aid in the 
central-nervous compensation that takes place after a pa-
tient has suffered from an attack [Redon et al., 2011]. 
Lastly, it has been shown that betahistine is capable of 
increasing cochlear blood flow in animal models and 
could therefore aid in the reduction of the endolymphat-
ic hydrops [Dziadziola et al., 1999; Laurikainen et al., 
2000; Ihler et al., 2012a]. So far, this has been viewed as 
the most likely mechanism of action in Ménière’s disease 
[Strupp et al., 2011].
 Betahistine is a structural analog of histamine that has 
been shown to act as a potent inverse agonist on hista-
mine H 3 -receptors [Gbahou et al., 2010] and as a weaker 
agonist on H 1 -receptors [Fossati et al., 2001]. It is com-
monly accepted that betahistine has no effect whatsoever 
on histaminergic H 2 -receptors [Curwain et al., 1972; Lau-
rikainen et al., 1998; Fossati et al., 2001]. Moreover, there 
have been results that suggest that betahistine also affects 
another class of receptors, potentially of the adrenergic 
α-receptor subfamily [Dziadziola et al., 1999]. To this 
day, the receptors by which betahistine increases cochlear 
microcirculation have not been investigated systemati-
cally and have only been assessed in a scattered manner. 
A potential cause for this is the early approval of betahis-
tine in the late 60s of the previous century, when a con-
siderably lower pharmacological understanding of a drug 
was required for approval. Moreover, the exact mode of 
action of betahistine at the histaminergic H 3 -receptor was 
only been discovered in 2010 [Gbahou et al., 2010]. To 
this day, the receptors investigated as mediators of beta-
histine effects have included histaminergic [Laurikainen 
et al., 1998; Dziadziola et al., 1999], cholinergic [Lauri-
kainen et al., 1993], adrenergic [Laurikainen et al., 1998] 
and imidazole receptors [Laurikainen et al., 1998].
 The aim of this study was to systematically evaluate the 
receptor or receptors that give rise to the increase in co-
chlear blood flow caused by betahistine.
 Materials and Methods 
 Animals 
 A total of 54 healthy female Dunkin-Hartley guinea pigs (180–
300 g) obtained from Charles River Laboratories (Sulzfeld, 
 Germany) were included in the study. All experiments were per-
formed according to German state regulations for animal experi-
mentation and were approved by the responsible authorities, the 
Niedersächsische Landesamt für Verbraucherschutz und Lebens-
mittelsicherheit (LAVES, Oldenburg, Germany; animal license 
No. 33.11.42502-04-012/889).
 The animals initially received buprenorphine 0.05 mg/kg body 
weight subcutaneously. Approximately 30 min after the initial ap-
plication of buprenorphine, the animals were sedated using a mix-
ture of ketamine (8.5 mg/kg body weight) and midazolam (0.75 mg/
kg body weight). After the animals were fully sedated, anesthesia 
was continued throughout the experiments by the continuous in-
halation of 3% isoflurane.
 The preparative surgery in the experiments lasted on average 
about 90 min and the measurements 18 min. Following the ex-
periments, the animals were euthanized.
 Surgical Preparation and Intravital Imaging 
 Surgical preparation and intravital microscopy for measuring 
microcirculation parameters were performed as described else-
where [Canis et al., 2010; Ihler et al., 2012b]. Utilizing microsur-
gery, a polyethylene catheter was placed in the left jugular vein for 
the application of fluids, agents and contrast material. A pressure 
transducer was placed in the right femoral artery. Finally, the right 
ear was removed and the underlying bulla carefully opened. A rect-
angular window of approximately 0.2 × 0.2 mm was carved into 
the exposed cochlea. 
 As previously described, intravital microscopy allowed direct 
examination and recording of stria vascularis vessels [Nuttall, 
1987]. Utilizing FITC (fluorescein isothiocyanate)-labeled dextran 
(molecular weight 500,000; 0.2–0.4 ml of a 5% solution in 0.9% 
NaCl; Sigma, Deisenhofen, Germany) that had been injected intra-
venously as a plasma marker, it was possible to differentiate the 
intravasal erythrocytes from the FITC-dyed plasma. The images 
were obtained using illumination with a Leica EL6000 light source 
(Leica Microsystems, Wetzlar, Germany) linked to a Leica M205 
FA stereomicroscope. The data generated was processed with the 
proprietary Leica Application Suite software and then saved on a 
digital hard drive for later off-line analysis. Velocity (micrometers 
per second) and diameter (micrometers) of stria vascularis vessels 
were measured after the surgical procedure with the image analy-
zation system Cap-Image (Dr. Zeintl Biomedical Engineering, 
Heidelberg, Germany) [Zeintl et al., 1989; Klyscz et al., 1997]. Dur-
ing analysis of the acquired data, three representative vessels for 
each animal were selected. For these vessels, three values for intra-
vascular blood flow and three values for the respective diameter 
were obtained each minute. These values were then averaged for 
each minute and, utilizing the formula postulated by Baker and 
Wayland, they were used to calculate the intravascular blood flow 
for each minute. The formula was given as q = (v/1.6) × (d/2) 2 × π, 
where q represents the intravascular blood flow, v the intravascular 
velocity and d the vessel diameter [Baker and Wayland, 1974]. In 
order to correct for interindividual differences, cochlear blood 
flow was reported in arbitrary units (AU), thus reflecting the rela-
tive change from the initially obtained basal values.
 The originally obtained basal values for intravascular blood 
flow ranged from 2 to 56 μl/s, depending on the animal and vessel 
examined. Potential reasons for this wide range of data sets include 
a possible impairment or injury of the vessels during the surgical 
preparation or drying out of the capillaries during fluorescence 
microscopy. Moreover, the fewer times a capillary had branched 
up before the point in which the measurements were taken, the 
greater the diameter and the larger the intravasal blood flow. To 
calculate relative change in cochlear blood flow, an average of the 
three basal values of each vessel was calculated. Any value record-
ed in this vessel was then divided by this average basal value. Fi-
nally, an average value for each minute was calculated from the 
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 Measurement of Mean Arterial Pressure 
 Mean arterial pressure was recorded using a Fiber-Optic Pres-
sure Measurement System by Samba Sensors AB (Västra Frölunda, 
Sweden) [Woldbaek et al., 2003]. The fiber-optic catheter was in-
serted into the right femoral artery. For the duration of the exper-
iments, the results were automatically recorded with a Samba 201 
Control Unit, with a rate of 40 measurements per second. The en-
suite Samba 200 control software was used for later analysis of the 
acquired data. The basal data sets for mean arterial pressure ranged 
from 14 to 79 mm Hg. Potential reasons for this data set include 
early circulatory failure caused by prolonged surgical preparation 
and interindividually different reactions to the anesthesia caused 
by variations in age or weight of the animals. 
 To correct for differences between individual animals, changes 
in blood pressure are reported as AU, reflecting the relative change. 
AUs were calculated by dividing each value obtained for mean ar-
terial pressure by an average of the three basal values obtained for 
each individual.
 Calculation of Normalized Cochlear Blood Flow 
 Normalized cochlear blood flow [Baldwin et al., 1992; Ohlsen et 
al., 1992] was calculated by dividing the obtained arbitrary values for 
cochlear blood flow by the arbitrary values obtained for the mean 
arterial pressure, allowing us to report a relative change in cochlear 
blood flow without units, corrected for potential systemic influences.
 Treatment Protocol 
 The 54 animals were randomly assigned to one of nine 
groups (betahistine plus placebo, betahistine plus demethylbeta-
histine, betahistine plus diphenhydramine, betahistine plus 
α-methylhistamine, betahistine plus thioperamide, betahistine 
plus proxyfan, betahistine plus idazoxan, betahistine plus yohim-
bine, ciproxifan without betahistine) and underwent microsurgery 
as reported above. As soon as a clear picture could be taken, base-
line measurements were recorded for 3 min. After the baseline 
measurements had been acquired, a 2-min infusion of the appro-
priate treatment was begun. Upon the beginning of the infusion, 
both cochlear blood flow and mean arterial pressure were record-
ed for 15 more minutes.
 Statistical Analysis 
 Statistical analysis was carried out by Project R for Mac 3.0.0 
GUI 1.60 Snow Leopard build (The R Foundation for Statistical 
Computing; http://www.r-project.org). Two-way analysis of vari-
ance (ANOVA) was used to detect significant differences; measure-
ments of the treatment groups were compared with placebo at each 
given time point. In order to correct for multiple testing for differ-
ent groups and time points, a Bonferroni t test was performed. A p 
value of α < 0.05 was considered to be statistically significant.
 Results 
 The Effect of Histaminergic H 1 -Receptors on Cochlear 
Blood Flow and Normalized Cochlear Blood Flow 
 Infusion of betahistine together with demethylbetahis-
tine, a histaminergic H 1 -receptor agonist, caused a gen-
eral drop in cochlear blood flow. From min 5 onwards, in 
which cochlear blood flow showed a brief increase, blood 
flow remained at a plateau around baseline level up to 
minute 11 (mean value for minutes 4–11  = 1.008 AU, 
standard deviation, SD = 0.116); from then on there was 
a strong tendency for blood flow to decrease. The average 
for the group receiving betahistine together with placebo 
in the same period of time was 1.180 AU (SD = 0.235). 
The lowest value was 0.766 AU at minute 18.
 The group receiving betahistine together with the H 1 -
antagonist diphenhydramine showed no significant dif-
ferences to the group that was treated with betahistine 
together with placebo.
 None of the groups treated with betahistine plus di-
phenhydramine or betahistine showed a significant im-
pact on normalized cochlear blood flow in comparison 
with the control group that was treated with betahistine 
together with a placebo ( fig. 1 , 2 ).
 The Effect of Histaminergic H 3 -Receptors on Cochlear 
Blood Flow and Normalized Cochlear Blood Flow 
 Infusion of the histamine H 3 -receptor agonist 
α-methylhistamine showed significant differences in 
comparison with control from minutes 6 to 18. There was 
a general tendency of the cochlear blood flow to decrease 
under infusion of α-methylhistamine; the average value 
for minutes 6–18 was at 0.805 AU (SD = 0.225). The aver-
age for the placebo group in the same period of time was 
1.219 AU (SD = 0.176).
 The group receiving the histamine H 3 -receptor antag-
onist thioperamide together with betahistine showed no 
major elevation from baseline; the changes in cochlear 
blood flow typical for betahistine were reversed. The 
mean value for minutes 4–18 was 0.994 AU (SD = 0.101). 
The values from minutes 7 to 18 are significantly different 
from the group receiving betahistine with placebo.
 The same can be said about the group receiving the 
H 3 -protean agonist proxyfan simultaneously with beta-
histine. Cochlear blood flow did not differ greatly from 
baseline throughout the entire observation. Minutes 8–18 
differed significantly from the placebo group.
 In the group that had received ciproxifan without be-
tahistine, a H 3 -selective inverse agonist/antagonist 
showed slightly increased cochlear blood flow. The aver-
age value for minutes 4–18 was 1.091 AU (SD = 0.063). 
Minutes 9–12 were significantly different from the beta-
histine group receiving solely betahistine.
 No significant changes in normalized cochlear blood 
flow were observed in any group treated with betahistine 
together with histaminergic H 3 -receptor agonists or an-




















   
   
   
   
   
   
   
   
   
   
   


























 The Effect of Adrenergic α 2 -Receptors on Cochlear 
Blood Flow and Normalized Cochlear Blood Flow 
 The group receiving idazoxan showed a slight initial 
drop in cochlear blood flow. The lowest value at minute 
4 was 0.889 AU (SD = 0.059). After a recovery up to min-
ute 3, cochlear blood flow remained steady around base-
line level. The average for minutes 7–18 was 1.011 AU 
(SD = 0.046). Minutes 5–17 were significantly different 
from the placebo group.
 Infusion of betahistine together with yohimbine 
showed no change from basal values upon infusion or in 
the period thereafter. Cochlear blood flow in minutes 
7–16 was significantly different from cochlear blood flow 
in the group receiving betahistine together with placebo.
 None of the groups treated with betahistine and adren-
ergic α 2 -receptor antagonists displayed significant chang-
es in normalized cochlear blood flow in comparison with 
the group receiving betahistine with placebo ( fig. 1 , 2 ).
 The Effect of H 1 -Receptors on Mean Arterial Pressure 
 The group that was treated with demethylbetahistine 
showed an initial, yet steep, rise with a peak at minute 5 
of 1.374 AU (SD = 0.496). From then on, blood pressure 





 Fig. 1. Cochlear blood flow over time before and after infusion of 
betahistine together with treatment.  a Betahistine plus demethyl-
betahistine.  b Betahistine plus diphenhydramine.  c Betahistine 
plus α-methylhistamine.  d Betahistine plus thioperamide.  e Beta-
histine plus proxyfan.  f Ciproxifan.  g Betahistine plus idazoxan. 
 h  Betahistine plus yohimbine. Data are presented as means ± SD. 
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ences from placebo were detected at minutes 5 and 9–18. 
The group receiving diphenhydramine showed no signif-
icant differences from the control group ( fig. 3 ).
 The Effect of H 3 -Receptors on Mean Arterial Pressure 
 Infusion of α-methylhistamine caused a steep increase 
for minutes 4–6. The peak was at minute 5 at 1.271 AU 
(SD = 0.296). From then on, blood pressure gradually de-
clined to 0.556 AU (SD = 0.222). The arterial pressure was 
statistically different from the control group at minutes 5 
and 8–18.
 Treatment with betahistine in combination with 
thioperamide reversed the betahistine-typical changes 
and caused blood pressure to remain close to basal values. 
Significant differences from the control group were mon-
itored at minutes 8–11.
 The group receiving proxyfan together with betahis-
tine showed similar effects to the aforementioned, mean-
ing little deviation from baseline. Moreover, there was an 
overall tendency for blood pressure to decrease; in com-
parison with the control group, values at minutes 9 and 
10 were significantly different.
 Treatment with only ciproxifan led to no significant 
changes in blood pressure compared with the control 
group ( fig. 3 ).
 The Effect of Adrenergic α 2 -Receptors on Arterial 
Blood Pressure 
 Infusion of betahistine in combination with idazoxan 
caused an initial, slight drop in blood pressure, while 
overall there was little change from basal values. In com-

























   
   
   
   
   
   
   
   
   
   
   


























solution, values for minutes 8–11 were significantly dif-
ferent.
 Treatment with yohimbine caused a similar effect, with 
an initial slight drop and the overall tendency for blood 
pressure to stay close to basal values. Comparison with the 
control group showed minutes 8, 9 and 10 to be signifi-
cantly different ( fig. 3 ). See supplementary table 1 for the 
effects of all histaminergic receptors. For an overview of 
the mechanism of action, structure, receptor affinities, 
and dosages of receptor agonists and antagonists used, 
see  online supplementary table  1 (for all online suppl. 
 material, see www.karger.com/doi/10.1159/000368293). 
 Discussion 
 Betahistine is known to act as a weak agonist on the 
H 1 -receptor [Gbahou et al., 2010]. Assuming that the 
increase in cochlear blood flow is mediated through the 
H 1 -receptor, one would expect betahistine in combina-
tion with an H 1 -selective agonist like demethylbetahis-
tine [Arai and Chiba, 1999] to cause an increase in co-
chlear blood flow at least comparable in extent with that 
of betahistine alone. In turn, one would expect treat-
ment with an H 1 -receptor antagonist like diphenhydr-
amine to reverse the increase in cochlear blood flow. 
 Fig. 2. Normalized cochlear blood flow over time before and after 
infusion of betahistine together with treatment.  a Betahistine plus 
demethylbetahistine.  b Betahistine plus diphenhydramine.  c Beta-
histine plus α-methylhistamine.  d Betahistine plus thioperamide. 
 e Betahistine plus proxyfan.  f Ciproxifan.  g Betahistine plus id-
azoxan.  h Betahistine plus yohimbine. Data are presented as 
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However, infusion of betahistine and demethylbetahis-
tine caused a drop in mean arterial pressure and cochle-
ar blood flow. It has previously been described before 
both betahistine and demethylbetahistine are capable of 
reducing blood pressure considerably [Tobia et al., 
1974]. Overall, the data presented here concerning de-
methylbetahistine could be a result of the progressive 
failure of cochlear blood flow autoregulation due to the 
continuously decreasing mean arterial pressure [Brown 
and Nuttall, 1994]. During minutes 4–11 cochlear blood 
flow is most likely to be in a steady state – maintained by 
autoregulation – whilst from minute 11 onwards, co-
chlear blood flow decreases owing to the failure of auto-
regulation due to the systemic decline of blood pressure. 
This view is further supported by the increasing values 
of normalized cochlear blood flow seen from minute 9 
onwards. With these assumptions in mind, it seems im-
probable that the H 1 -agonism of betahistine plays a ma-
jor role in the mediation of betahistine effects. Fittingly, 
the group treated with the H 1 -antagonist diphenhydr-
amine yielded no significant differences from the con-
trol group in terms of cochlear blood flow or arterial 
pressure in the present study. These findings are in line 
with the literature that suggests that the H 1 -receptor has 
no effect on betahistine-induced effects on cochlear 
blood flow [Laurikainen et al., 1993]. However, one 
more observation should be pointed out here: in previ-
ous experiments it has been shown that higher doses of 
betahistine show a significant yet short-lived drop in 
mean arterial pressure and cochlear blood flow at the 
beginning of betahistine infusion [Ihler et al., 2012a].

























   
   
   
   
   
   
   
   
   
   
   


























er the concentration of betahistine [Dziadziola et al., 
1999]. A similar although smaller drop (owing to our 
relatively low dosage of betahistine) was observed in the 
data presented here. The results of the diphenhydramine 
group suggest that this initial drop could potentially be 
reversed by the application of an H 1 -antagonist such as 
diphenhydramine. Bearing in mind the previous as-
sumption that the H 1 -agonism of betahistine is most 
likely not involved in the increase of cochlear blood 
flow, it seems very possible that it is involved in the me-
diation of this initial drop in mean arterial pressure. 
These findings are in line with recent receptor affinity 
studies that pointed out that betahistine is very potent at 
the H 3 -receptor and somewhat weaker at the H 1 -recep-
tor [Fossati et al., 2001; Gbahou et al., 2010], raising the 
idea that side effects of betahistine, like the aforemen-
tioned drop in mean arterial pressure and cochlear 
blood flow, could be H 1 -mediated. This view is support-
ed by the fact that typical betahistine side effects are also 
typically H 1 -receptor-related reactions, including flush-
ing, headaches, skin reactions, and low blood pressure 
[Parsons, 1991; Jeck-Thole and Wagner, 2006].
 Betahistine acts as a potent inverse agonist at the H 3 -
receptor [Gbahou et al., 2010]. An inverse agonist is a li-
 Fig. 3. Mean arterial pressure over time before and after infusion 
of betahistine together with treatment.  a Betahistine plus demeth-
ylbetahistine.  b Betahistine plus diphenhydramine.  c Betahistine 
plus α-methylhistamine.  d Betahistine plus thioperamide.  e Beta-
histine plus proxyfan.  f Ciproxifan.  g Betahistine plus idazoxan. 
 h  Betahistine plus yohimbine. Data are presented as means ± SD. 
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gand that binds to a receptor and decreases its constitu-
tive activity [Kenakin and Williams, 2014]. Blocking of 
the H 3 -receptor with proxyfan or thioperamide caused 
the suppression of changes in cochlear blood flow typi-
cally mediated by betahistine. The suppression of betahis-
tine-induced changes in cochlear blood flow by the block-
age of the H 3 -receptor has previously  been reported [Dzi-
adziola et al., 1999] and was also observed in the present 
study. This indicates an involvement of the H 3 -receptor 
in betahistine-induced changes in cochlear blood flow. 
The fact that infusion of betahistine together with the H 3 -
receptor agonist α-methylhistamine, which acts as an op-
ponent on this receptor in comparison with betahistine, 
caused a significant and lasting drop in both cochlear 
blood flow and mean arterial pressure further supports 
this theory. The fact that α-methylhistamine in combina-
tion with betahistine decreases cochlear blood flow and 
arterial blood pressure has not been reported so far and 
contradicts a study that conducted a similar experiment 
[Laurikainen et al., 1998]. In this study it had been pro-
posed that α-methylhistamine had no effect whatsoever 
on cochlear blood flow or blood pressure. However, in the 
aforementioned study, α-methylhistamine dosaging had 
been more than 10-fold lower, whilst betahistine concen-
trations were 15 times higher than in this setting, result-
ing in an agonist-to-betahistine ratio of over 150 times 
lower than in the experiments reported here. Hence, the 
overall results indicated a probable involvement of the 
histamine H 3 -receptor in betahistine effects on cochlear 
blood flow. In order to elucidate this theory, one group 
was treated solely with ciproxifan, a competitive H 3 -in-

























   
   
   
   
   
   
   
   
   
   
   


























ciproxifan caused a moderate increase in both cochlear 
blood flow and mean arterial pressure – however, not to 
an extent comparable with that of betahistine. A possible 
reason for this finding could be a relatively low affinity to 
adrenergic α 2 -receptors, which also seem to be involved 
in the mediation of betahistine-induced effects on cochle-
ar blood flow and mean arterial pressure. Finally, even 
though ciproxifan has a lower K i value than betahistine at 
the histaminergic H 3 -receptor, and thus a greater affinity, 
this does not imply a stronger effect on the intracellular 
signaling cascades controlled by H 3 -receptors.
 Taking into account all of the above considerations, it 
seems likely that the histamine H 3 -receptor plays a major 
role in the observed betahistine effects on cochlear blood 
flow. 
 It has been suggested several times that betahistine ef-
fects are not only mediated by histamine receptors, but 
that another class of receptors is involved as well. Candi-
dates for this second receptor class have included acetyl-
choline [Laurikainen et al., 1993], imidazole [Laurikainen 
et al., 1998] and adrenergic [Laurikainen et al., 1998] re-
ceptors. It has been reported that pretreatment of animals 
with idazoxan, a potent adrenergic α 2 -receptor antago-
nist, is capable of entirely reversing the betahistine-in-
duced changes in cochlear blood flow [Laurikainen et al., 
1998]. To the best of our knowledge, there have been no 
in vivo or in vitro investigations on the extent to which 
betahistine exerts an effect on α 2 -receptors. In the pre-
sented data, betahistine effects were reversed by simulta-
neous infusion of both idazoxan, an α 2 -/I 2 -receptor an-
tagonist, and yohimbine, an α 2 -/5-HT 3 -antagonist, to-
gether with betahistine. Overall, the fact that blockage of 
the α 2 -receptor can also reverse betahistine changes sim-
ilar to proxyfan and thioperamide suggests a noteworthy 
involvement of adrenergic α 2 -receptors in betahistine ef-
fects too. This view is further supported by the fact that 
betahistine was originally discovered as a drug while 
searching for adrenergic properties of pyridylalkylamines 
[Hunt and Fosbinder, 1942].
 The fact that both the α 2 - and the H 3 -receptor obvi-
ously play a major role in the mediation of betahistine ef-
fects raises a new question: do both receptors contribute 
directly to the increase in cochlear blood flow or could it 
be that they function as heteroreceptors that influence 
each other. Overall, the latter theory seems somewhat 
more likely, bearing in mind the fact that H 3 -receptors are 
known to have a significant impact on systemic and local 
noradrenaline release [Malinowska et al., 1998; Mazenot 
et al., 1999]. Moreover, it has been shown that H 3 -recep-
tors are capable of interacting both with histaminergic 
and autonomic receptors in the periphery [Ishikawa and 
Sperelakis, 1987].
 Taking this assumption even further, it could be pos-
tulated that the effects of betahistine at the cochlea are 
mere downstream effects caused by the increased blood 
pressure. Such a view could be supported by the fact 
that the cochlea lacks short-term autoregulation when 
systemic blood pressure increases [Vass et al., 1993], and 
that even successful betahistine therapy has failed to 
show a considerable impact on the endolymphatic hy-
drops on Ménière’s patients [Gurkov et al., 2013]. Fit-
tingly, none of the groups presented in this study hap-
pened to show a significant impact on normalized co-
chlear blood flow. However, it has also been shown that 
betahistine has a direct effect on vessels [Laurikainen et 
al., 1998; Santos-Silva et al., 2009]. In addition to that, 
a study conducted by this workgroup managed to show 
a significant increase of cochlear blood flow caused by 
the infusion of aminoethylpyridine, a product of beta-
histine metabolism [Bertlich et al., 2014]. At the same 
time, aminoethylpyridine had the tendency to lower 
mean arterial pressure, suggesting that betahistine ef-
fects are at least partially specific to the cochlear capil-
lary network.
 Conclusion 
 Betahistine effects seem to be mediated through hista-
mine H 3 -receptors. Furthermore, the data presented here 
indicate an involvement of the adrenergic α 2 -receptors. 
The exact role of the adrenergic α 2 -receptors could be ex-
plained with the heteroreceptor properties of the H 3 - 
receptor.
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